Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093652 · ClinicalTrials.gov registry record · Phase 1
Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00093652: Clinical Trial Phase 1 study, sponsored by Roswell Park Cancer Institute.
NCT00093652 is a Phase 1 study that was terminated before completion, run by Roswell Park Cancer Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00093652, a Phase 1 study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining oxaliplatin and gefitinib with radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of oxaliplatin when given together with gefitinib and radiation therapy and to see how well they work in treating patients with locally advanced or metastatic esophageal cancer.
Interventions
- DRUG oxaliplatin
- PROCEDURE conventional surgery
- RADIATION radiation therapy
- DRUG gefitinib
- PROCEDURE neoadjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-05 |
| Phase | Phase 1 |
Why NCT00093652 stopped before completion
NCT00093652 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which oxaliplatin is the first listed.
NCT00093652 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00093652 about?
NCT00093652 is a clinical study titled "Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer". RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to damage tumor...
What is the current status of trial NCT00093652?
This trial is currently terminated. It is a Phase 1 study. The study started on 2003-05.
What interventions are being tested in trial NCT00093652?
The interventions under investigation include: oxaliplatin (DRUG), conventional surgery (PROCEDURE), radiation therapy (RADIATION), gefitinib (DRUG), neoadjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00093652?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia